Company intelligence / Profile preview

Allygen Biologics

Shanghai, Shanghai, Chinaallogenbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ALG01, a next-generation anti-PD-L1×TROP-2 bispecific antibody-drug conjugate (BiADC) with STAR technology, demonstrated excellent anti-tumor efficacy and safety in preclinical studies. In toxicology studies, ALG01 was well tolerated in cynomolgus monkeys, with the highest non-severely toxic dose (HNSTD) observed at ≥45 mg/kg for DAR6 or ≥65 mg/kg for DAR4. An IND application is planned for submission in 2025.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)Bispecific antibodies
Industry: Biotech

Drug pipeline

1 asset

PD-L1-SN-38 ADC

Pre-clinical

Indications: Cancer

Beyond the preview

Go deeper on Allygen Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allygen Biologics.

Explore the full profile